MCID: TCL027
MIFTS: 52

T-Cell Acute Lymphoblastic Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for T-Cell Acute Lymphoblastic Leukemia

MalaCards integrated aliases for T-Cell Acute Lymphoblastic Leukemia:

Name: T-Cell Acute Lymphoblastic Leukemia 12 36 29 6 15 17
Precursor T Cell Lymphoblastic Leukemia/lymphoblastic Lymphoma 70
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 70
Precursor T-Lymphoblastic Lymphoma/leukemia 12
Precursor T-Cell Lymphoblastic Lymphoma 70
Leukemia, Acute, Lymphoblastic, T-Cell 39
Leukemia, T-Cell Acute Lymphoblastic 39
Precursor T Lymphoblastic Leukemia 12
T-Cell Acute Lymphocytic Leukaemia 12
T Acute Lymphoblastic Leukemia 12
Acute T Cell Leukaemia 12
Leukemia, Acute T-Cell 39
Acute T Cell Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5603
KEGG 36 H00002
MeSH 44 D015459
NCIt 50 C3184
SNOMED-CT 67 77430005
ICD10 32 C91.5
UMLS 70 C0023493 C1292758 C1301359 more

Summaries for T-Cell Acute Lymphoblastic Leukemia

KEGG : 36 Acute lymphocytic leukemia (ALL) is a clonal stem cell malignancy of excessive lymphoblast proliferation. It is now understood that ALL and lymphoblastic lymphoma are the same disease entities at the morphologic and immunophenotypic levels and classified as either B- and T-cell lymphoblastic leukemia/lymphoma (B-ALL and T-ALL). T-ALL comprises 15% of paediatric and 25% of adult ALL cases. T cell transformation is a multi-step process in which different genetic alterations cooperate to alter the normal mechanisms that control cell growth, proliferation, survival, and differentiation during thymocyte development. In this context, constitutive activation of NOTCH1 signaling is the most prominent oncogenic pathway in T cell transformation. In addition, T-ALLs characteristically show the translocation and aberrant expression of transcription factor oncogenes. These oncogenic transcription factors include T-cell leukaemia homeobox protein 1 (TLX1 also known as HOX11), TLX3 (HOX11L2), LYL1, TAL1 and MLL.

MalaCards based summary : T-Cell Acute Lymphoblastic Leukemia, also known as precursor t cell lymphoblastic leukemia/lymphoblastic lymphoma, is related to precursor t-cell acute lymphoblastic leukemia and childhood t-cell acute lymphoblastic leukemia. An important gene associated with T-Cell Acute Lymphoblastic Leukemia is BAX (BCL2 Associated X, Apoptosis Regulator), and among its related pathways/superpathways are Transcriptional misregulation in cancer and NF-kappaB Signaling. The drugs Dexrazoxane and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and myeloid, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 An acute lymphoblastic leukemia that is characterized by too many T-cell lymphoblasts found in the bone marrow and blood.

Related Diseases for T-Cell Acute Lymphoblastic Leukemia

Diseases related to T-Cell Acute Lymphoblastic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 224)
# Related Disease Score Top Affiliating Genes
1 precursor t-cell acute lymphoblastic leukemia 33.5 TLX3 TLX1 TAL1 NUP98 NOTCH1 LYL1
2 childhood t-cell acute lymphoblastic leukemia 33.2 TAL1 IL2 ABL1
3 leukemia, acute lymphoblastic 33.1 TLX3 TLX1 TAL1 NOTCH1 NALT1 LYL1
4 leukemia 32.3 TLX3 TLX1 TCL6 TAL2 TAL1 NUP98
5 t-cell lymphoblastic leukemia/lymphoma 32.0 TLX1 TAL1 NOTCH1 LMO2 LMO1 LCK
6 lymphoblastic lymphoma 31.9 TLX1 TAL1 NOTCH1 LMO2
7 leukemia, acute myeloid 31.9 TAL1 NUP98 NOTCH1 LMO2 LCK IL2
8 acute leukemia 31.9 TAL1 NUP98 NOTCH1 IL2
9 severe combined immunodeficiency 31.6 NOTCH1 LMO2 LCK IL2
10 lymphoma 31.5 TLX1 TCL6 TAL1 IL2 BCL10 BAX
11 leukemia, chronic lymphocytic 31.3 NOTCH1 LCK IL2 BCL10 BAX ATM
12 lymphoma, non-hodgkin, familial 31.1 TAL1 NOTCH1 LCK IL2 BCL10 BAX
13 hematologic cancer 31.1 NUP98 NOTCH1 IL2 ATM ABL1
14 combined immunodeficiency 31.0 NOTCH1 LMO2 LCK IL2 BCL10 ATM
15 myelodysplastic syndrome 30.9 NUP98 NOTCH1 IL2 ATM ABL1
16 refractory t lymphoblastic leukemia/lymphoma 11.5
17 t-cell adult acute lymphocytic leukemia 11.4
18 pdgfra-associated chronic eosinophilic leukemia 11.4
19 lymphosarcoma 11.3
20 leukemia, t-cell, chronic 10.9
21 b-lymphoblastic leukemia/lymphoma 10.8
22 myeloid leukemia 10.7
23 interleukin-7 receptor alpha deficiency 10.6
24 adult acute lymphocytic leukemia 10.6
25 b-cell lymphoma 10.6
26 helix syndrome 10.6
27 glucocorticoid resistance, generalized 10.5
28 47,xyy 10.5
29 leukemia, chronic myeloid 10.5
30 graft-versus-host disease 10.5
31 childhood acute lymphocytic leukemia 10.5
32 neutropenia 10.5
33 cowden syndrome 1 10.4
34 ataxia-telangiectasia 10.4
35 lung disease, immunodeficiency, and chromosome breakage syndrome 10.4
36 adult t-cell leukemia 10.4
37 pancytopenia 10.4
38 telangiectasis 10.4
39 myeloproliferative neoplasm 10.4
40 acute kidney failure 10.4
41 histiocytosis 10.4
42 cowden syndrome 10.4
43 chromosomal triplication 10.4
44 b-lymphoblastic leukemia/lymphoma with etv6-runx1 10.4 TLX1 LYL1
45 ataxia and polyneuropathy, adult-onset 10.4
46 langerhans cell histiocytosis 10.4
47 deficiency anemia 10.4
48 childhood leukemia 10.4
49 48,xyyy 10.4
50 acute graft versus host disease 10.4

Graphical network of the top 20 diseases related to T-Cell Acute Lymphoblastic Leukemia:



Diseases related to T-Cell Acute Lymphoblastic Leukemia

Symptoms & Phenotypes for T-Cell Acute Lymphoblastic Leukemia

MGI Mouse Phenotypes related to T-Cell Acute Lymphoblastic Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.14 ABL1 ATM BAX BCL10 IL2 LMO2
2 hematopoietic system MP:0005397 10.13 ABL1 ATM BAX BCL10 IL2 LCK
3 immune system MP:0005387 10.07 ABL1 ATM BAX BCL10 IL2 LCK
4 embryo MP:0005380 10.02 ABL1 ATM BCL10 LCK LMO2 NOTCH1
5 mortality/aging MP:0010768 9.97 ABL1 ATM BAX BCL10 IL2 LMO1
6 neoplasm MP:0002006 9.5 ATM BAX IL2 LMO2 NOTCH1 OLIG2
7 nervous system MP:0003631 9.44 ABL1 ATM BAX BCL10 LMO1 LMO2

Drugs & Therapeutics for T-Cell Acute Lymphoblastic Leukemia

Drugs for T-Cell Acute Lymphoblastic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 171)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexrazoxane Approved, Withdrawn Phase 3 24584-09-6 71384
2
Azathioprine Approved Phase 3 446-86-6 2265
3
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
4
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
5
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
6
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
7
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
9
Daunorubicin Approved Phase 3 20830-81-3 30323
10
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
11
Thioguanine Approved Phase 3 154-42-7 2723601
12
leucovorin Approved Phase 3 58-05-9 6006
13
Mercaptopurine Approved Phase 3 50-44-2 667490
14
Ichthammol Approved Phase 3 8029-68-3
15
Pegaspargase Approved, Investigational Phase 3 130167-69-0
16
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
17
Etoposide Approved Phase 3 33419-42-0 36462
18
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
19
Lenograstim Approved, Investigational Phase 3 135968-09-1
20
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
21
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
22
Bortezomib Approved, Investigational Phase 3 179324-69-7 93860 387447
23
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
24
Ifosfamide Approved Phase 3 3778-73-2 3690
25
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
26
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
27
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
28
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
29
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
30
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
31
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
32
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
33
Aclarubicin Investigational Phase 3 57576-44-0 451415
34
Cortisone Experimental Phase 3 53-06-5 222786
35
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
36
Homoharringtonine Phase 3 285033
37 Imatinib Mesylate Phase 3 220127-57-1 123596
38 razoxane Phase 3
39 Cardiotonic Agents Phase 3
40 Vitamin B9 Phase 3
41 Tubulin Modulators Phase 3
42 Alkylating Agents Phase 3
43
protease inhibitors Phase 3
44 2-Aminopurine Phase 3
45 Antibiotics, Antitubercular Phase 3
46 Nutrients Phase 3
47 Trace Elements Phase 3
48 Micronutrients Phase 3
49 Gastrointestinal Agents Phase 3
50 Hematinics Phase 3

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
2 A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients Recruiting NCT04446130 Phase 3 Decitabine combined with HAAG Regimen
3 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones Recruiting NCT03007147 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Dexrazoxane Hydrochloride;Doxorubicin;Etoposide;Ifosfamide;Imatinib Mesylate;Leucovorin Calcium;Mercaptopurine;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisolone;Therapeutic Hydrocortisone;Thioguanine;Vincristine Sulfate
4 Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma Active, not recruiting NCT00408005 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
5 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) Active, not recruiting NCT02112916 Phase 3 Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine;Vincristine Sulfate
6 A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) Active, not recruiting NCT00557193 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Etoposide;Lestaurtinib;Leucovorin Calcium;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisone;Therapeutic Hydrocortisone;Vincristine Sulfate
7 Phase I/II Study of Ruxolitinib Plus L-asparaginase, Vincristine, and Prednisone in Adult Patients With Relapsed or Refractory Early T Precursor Acute Lymphocytic Leukemia Unknown status NCT03613428 Phase 1, Phase 2 Ruxolitinib;Vincristine;Prednisone
8 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
9 A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients Completed NCT02518113 Phase 1, Phase 2 LY3039478;Dexamethasone;Placebo
10 Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia Completed NCT00061048 Phase 2
11 Transfusion of CD45RA-depleted Donor Lymphocytes to Improve Regeneration of Antimicrobial Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
12 Phase II-Study With Nelarabine in Patients With Refractory Oder Relapsed T- ALL or T-lymphoblastic Lymphoma (Amend.7) Completed NCT00684619 Phase 2 Nelarabine
13 A Phase II Trial of 506U78 (IND 52611) in Patients With Relapsed or Refractory Non T-cell Acute Lymphoblastic Leukemia (ALL) Completed NCT00006020 Phase 2 nelarabine
14 A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) Recruiting NCT04315324 Phase 2 AKR1C3-activated Prodrug OBI-3424
15 A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies Recruiting NCT04033302 Phase 1, Phase 2
16 An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting NCT03384654 Phase 2 Daratumumab;Vincristine;Prednisone;Doxorubicin;Cyclophosphamide;Cytarabine;6-mercaptopurine;Methotrexate
17 Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma Recruiting NCT00501826 Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Venetoclax;Vincristine Sulfate
18 A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma Recruiting NCT02763384 Phase 2 BL-8040;Nelarabine
19 Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Recruiting NCT03808610 Phase 1, Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Venetoclax;Vincristine
20 A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia Recruiting NCT03504644 Phase 1, Phase 2 Venetoclax;Vincristine Liposomal
21 A Phase II Study of Venetoclax in Combination With Azacitidine in the Post-Transplant Setting for AML, T Cell ALL, and Mixed Phenotype Acute Leukemia Recruiting NCT04128501 Phase 2 Azacitidine;Venetoclax
22 Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia in First or Second Relapse Recruiting NCT03860844 Phase 2 Montelukast;Isatuximab;Dexamethasone;Fludarabine;Cytarabine;Liposomal daunorubicin;Daunorubicin;Idarubicin;Filgrastim;Mitoxantrone;Doxorubicin;Vincristine;PEG Asparaginase;Cyclophosphamide;Etoposide;Methotrexate;L - Asparginase;Hydroxyurea;L - Asparaginase (Erwinase);Tocilizumab
23 A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) Active, not recruiting NCT02484430 Phase 2 Sapanisertib
24 Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study) Active, not recruiting NCT00792948 Phase 2 Cyclophosphamide;Cytarabine;Dasatinib;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Leucovorin Calcium;Methotrexate;Methylprednisolone;Prednisone;Sirolimus;Tacrolimus;Vincristine Sulfate
25 A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC Terminated NCT00981799 Phase 1, Phase 2 Nelarabine;Etoposide;Cyclophosphamide;Methotrexate;Filgrastim
26 A Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens. Terminated NCT00419081 Phase 2 Forodesine Hydrochloride Sterile Solution, 5 mg/mL;Forodesine Hydrochloride Capsules (100 mg)
27 A Phase II Study Incorporating Panobinostat, Bortezomib and Liposomal Vincristine Into Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Terminated NCT02518750 Phase 2 Dexamethasone;Panobinostat;Liposomal vincristine;Mitoxantrone;Peg-asparaginase;Bortezomib;Intrathecal Triples;High-dose methotrexate;6-Mercaptopurine;High-dose cytarabine;Nelarabine;Cyclophosphamide;Etoposide;Clofarabine
28 Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL) Terminated NCT02999633 Phase 2 Isatuximab SAR650984;dexamethasone;dexamethasone;acetaminophen;ranitidine;diphenhydramine
29 A Phase II Study of Anti-PD-1 Antibody (MK-3475; Pembrolizumab) for the Treatment of Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Terminated NCT02767934 Phase 2
30 A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Terminated NCT01483690 Phase 1, Phase 2 Decitabine;Vorinostat;Vincristine;Dexamethasone;Mitoxantrone;Pegaspargase;Methotrexate
31 A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's Lymphoma. Terminated NCT00742495 Phase 1, Phase 2 Forodesine
32 A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Asparaginase (DA-EPOCH-A) for Adults With Acute Lymphoblastic Leukemia/Lymphoma Withdrawn NCT02538926 Phase 2 Asparaginase;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Imatinib Mesylate;Prednisone;Vincristine Sulfate
33 Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed NCT01363817 Phase 1 BMS-906024;Dexamethasone
34 Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction Completed NCT00608361 Phase 1 Dasatinib
35 Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Hematologic Malignancies and Solid Tumors Completed NCT00640796 Phase 1 Chemotherapy
36 A Phase 1 Study of Temsirolimus in Combination With Intensive Re-induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma Completed NCT01403415 Phase 1 Dexamethasone;Methotrexate;Mitoxantrone Hydrochloride;Pegaspargase;Temsirolimus;Vincristine Sulfate
37 Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies Completed NCT01567709 Phase 1 Alisertib;Vorinostat
38 Clinical Evaluation of 506U78 in Japanese Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma. Completed NCT00406757 Phase 1 Nelarabine injection 400mg/m2;Nelarabine injection 650mg/m2;Nelarabine injection 1000mg/m2;Nelarabine injection 1500mg/m2
39 A PHASE I TRIAL OF PF-03084014 IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCY AND T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA Completed NCT00878189 Phase 1 PF-03084014
40 Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies Recruiting NCT04594135 Phase 1 anti-CD5 CAR T cells
41 A Phase I Dose Escalation Study With Expansion to Evaluate the Safety of SEPHB4-HSA in Combination With Cytarabine or Liposomal Vincristine in Patients With Relapsed or Refractory Acute Leukemia Recruiting NCT03519984 Phase 1 Cytarabine;Vincristine Liposomal
42 A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies Recruiting NCT04681105 Phase 1 Acetaminophen;Dexamethasone;Diphenhydramine;Ibuprofen;Ranitidine
43 Phase 1 Therapy With Manufactured Autologous T-Cells Expressing a Second Generation Chimeric Antigen Receptor (CAR) for Treatment of T-Cell Malignancies Expressing CD5 Antigen Recruiting NCT03081910 Phase 1 Fludarabine;Cytoxan
44 The Safety and Clinical Efficacy of Human TRBC1 CAR-T Cell Therapy for Patients With Relapsed/Refractory TRBC1 Positive T Cell Hematological Maliganacies Recruiting NCT04828174 Phase 1 anti-TRBC1 CAR-T cell therapy
45 A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias Active, not recruiting NCT01139970 Phase 1 Temozolomide;Veliparib
46 Cell Therapy for High Risk T-Cell Malignancies Using CD7-specific CAR Expressed On Autologous T Cells (CRIMSON) Not yet recruiting NCT03690011 Phase 1 Fludarabine;Cytoxan
47 A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) Terminated NCT01186328 Phase 1 EZN-3042;Cytarabine;Doxorubicin;Prednisone;Vincristine;PEG-asparaginase;Methotrexate;Hydrocortisone
48 A Phase I Study of a Gamma Secretase Inhibitor for Adult and Pediatric Patients With Relapsed or Refractory Acute T-Cell Lymphoblastic Leukemia and Lymphoma Terminated NCT00100152 Phase 1 MK0752, (Notch Inhibitor)
49 Evaluation of 304 Danish Girls With Tall Stature: Phenotypic Characteristics and Effects of Oral Administration of Natural 17β-Estradiol Unknown status NCT02638922 Estradiol
50 Four Years Experience With Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden. Population-based Data. Completed NCT01950286

Search NIH Clinical Center for T-Cell Acute Lymphoblastic Leukemia

Genetic Tests for T-Cell Acute Lymphoblastic Leukemia

Genetic tests related to T-Cell Acute Lymphoblastic Leukemia:

# Genetic test Affiliating Genes
1 T-Cell Acute Lymphoblastic Leukemia 29

Anatomical Context for T-Cell Acute Lymphoblastic Leukemia

MalaCards organs/tissues related to T-Cell Acute Lymphoblastic Leukemia:

40
T Cells, Bone Marrow, Myeloid, Liver, Endothelial, Thymus, Spleen

Publications for T-Cell Acute Lymphoblastic Leukemia

Articles related to T-Cell Acute Lymphoblastic Leukemia:

(show top 50) (show all 2209)
# Title Authors PMID Year
1
ABL1 rearrangements in T-cell acute lymphoblastic leukemia. 61 6
20073070 2010
2
Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. 6
27821800 2016
3
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 6
9989495 1999
4
Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. 6
9531611 1998
5
Decitabine inhibits the proliferation of human T-cell acute lymphoblastic leukemia molt4 cells and promotes apoptosis partly by regulating the PI3K/AKT/mTOR pathway. 61
33747197 2021
6
Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia. 61
32139432 2021
7
Synthesis of polyenylpyrrole derivatives with selective growth inhibitory activity against T-cell acute lymphoblastic leukemia cells. 61
33581250 2021
8
Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management. 61
33234511 2021
9
Multivalent Sgc8c-aptamer decorated polymer scaffolds for leukemia targeting. 61
33595548 2021
10
Rare KMT2A-ELL and Novel ZNF56-KMT2A Fusion Genes in Pediatric T-cell Acute Lymphoblastic Leukemia. 61
33608309 2021
11
Intracranial Hemorrhage Associated With T-Cell Acute Lymphoblastic Leukemia With Hyperleukocytosis: A Case Report. 61
33797454 2021
12
PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis. 61
32606318 2021
13
Retraction Note: Chrysophanol suppresses growth and metastasis of T cell acute lymphoblastic leukemia via miR-9/PD-L1 axis. 61
33247764 2021
14
Inhibition of BCL11B induces downregulation of PTK7 and results in growth retardation and apoptosis in T-cell acute lymphoblastic leukemia. 61
33663588 2021
15
Circular RNA circRNA_0000094 sponges microRNA-223-3p and up-regulate F-box and WD repeat domain containing 7 to restrain T cell acute lymphoblastic leukemia progression. 61
33677796 2021
16
DNA methylation-mediated silencing of microRNA-204 enhances T cell acute lymphoblastic leukemia by up-regulating MMP-2 and MMP-9 via NF-κB. 61
33566449 2021
17
CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia. 61
33306218 2021
18
Ultra-high-dose-rate FLASH and Conventional-Dose-Rate Irradiation Differentially Affect Human Acute Lymphoblastic Leukemia and Normal Hematopoiesis. 61
33075474 2021
19
RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. 61
33555272 2021
20
Adenylate kinase 2 expression and addiction in T-ALL. 61
33560378 2021
21
Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T cell Acute Lymphoblastic Leukemia. 61
33538669 2021
22
Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma. 61
33107983 2021
23
Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. 61
33639000 2021
24
TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition. 61
32409690 2021
25
Correction to: FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group. 61
33484418 2021
26
Deleterious point mutations in T-cell acute lymphoblastic leukemia: Mechanistic insights into leukemogenesis. 61
33634864 2021
27
SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia. 61
32382081 2021
28
The depletion of Circ-PRKDC enhances autophagy and apoptosis in T-cell acute lymphoblastic leukemia via microRNA-653-5p/Reelin mediation of the PI3K/AKT/mTOR signaling pathway. 61
33615686 2021
29
MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia. 61
33611795 2021
30
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia. 61
33597219 2021
31
Nelarabine in Pediatric and Young Adult T-Cell Acute Lymphoblastic Leukemia-Clearly Beneficial? 61
33444071 2021
32
Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia. 61
32812017 2021
33
Aggressive Langerhans cell histiocytosis transformation of T cell acute lymphoblastic leukemia detected on 18F-FDG PET/CT. 61
32504290 2021
34
The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy. 61
32929178 2021
35
Human T-ALL Xenografts. 61
33165851 2021
36
Successful Use of Nivolumab in a Patient with Head and Neck Cancer After Allogeneic Bone Marrow Transplantation. 61
33603397 2021
37
Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop. 61
33496749 2021
38
Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death. 61
33507291 2021
39
Erratum: Impact of microRNA-29b on nature killer cell in T-cell acute lymphoblastic leukemia. 61
33240418 2021
40
Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesis-Addicted Breast Tumor Growth. 61
33203732 2021
41
Differentiation of rare brain tumors through unsupervised machine learning: Clinical significance of in-depth methylation and copy number profiling illustrated through an unusual case of IDH wildtype glioblastoma. 61
32870144 2021
42
Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. 61
33408769 2021
43
A mathematical model of tumor regression and recurrence after therapeutic oncogene inactivation. 61
33446671 2021
44
T-ALL can evolve to oncogene independence. 61
33483615 2021
45
Notch Signaling and Human Papillomavirus-Associated Oral Tumorigenesis. 61
33034029 2021
46
Germline IKAROS dimerization haploinsufficiency causes hematologic cytopenias and malignancies. 61
32845957 2021
47
Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases. 61
32800789 2021
48
Retrospective Diagnosis of Ataxia-Telangiectasia in an Adolescent Patient With a Remote History of T-Cell Leukemia. 61
31743320 2021
49
FZD6 triggers Wnt-signalling driven by WNT10BIVS1 expression and highlights new targets in T-cell acute lymphoblastic leukemia. 61
33497493 2021
50
Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia. 61
33168453 2021

Variations for T-Cell Acute Lymphoblastic Leukemia

ClinVar genetic disease variations for T-Cell Acute Lymphoblastic Leukemia:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BAX NM_138761.4(BAX):c.199G>A (p.Gly67Arg) SNV Pathogenic 9513 rs398122513 GRCh37: 19:49459056-49459056
GRCh38: 19:48955799-48955799
2 BAX NM_138761.4(BAX):c.115_121del (p.Gly39fs) Deletion Pathogenic 9514 rs398122840 GRCh37: 19:49458971-49458977
GRCh38: 19:48955714-48955720
3 ABL1 Translocation Pathogenic 617566 GRCh37: 9:133709770-133709771
GRCh38:
4 BCL10 NM_003921.5(BCL10):c.136dup (p.Ile46fs) Duplication Pathogenic 6259 rs387906351 GRCh37: 1:85736510-85736511
GRCh38: 1:85270827-85270828

Copy number variations for T-Cell Acute Lymphoblastic Leukemia from CNVD:

7 (show top 50) (show all 91)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 21835 1 16200000 23900000 Copy number CHD5 T-cell acute lymphoblastic leukemia
2 21836 1 16200000 23900000 Copy number HES2 T-cell acute lymphoblastic leukemia
3 21837 1 16200000 23900000 Copy number HES3 T-cell acute lymphoblastic leukemia
4 32217 1 34600000 44100000 Copy number T-cell acute lymphoblastic leukemia
5 34248 1 5400000 7200000 Deletion T-cell acute lymphoblastic leukemia
6 38166 10 1 3800000 Copy number T-cell acute lymphoblastic leukemia
7 41844 10 24600000 31300000 Copy number ADARB2 T-cell acute lymphoblastic leukemia
8 41845 10 24600000 31300000 Copy number PFKP T-cell acute lymphoblastic leukemia
9 41846 10 24600000 31300000 Copy number PITRM1 T-cell acute lymphoblastic leukemia
10 41847 10 24600000 31300000 Copy number WDR37 T-cell acute lymphoblastic leukemia
11 46873 10 87900000 92900000 Loss PTEN T-cell acute lymphoblastic leukemia
12 48336 11 1 2800000 Gain IGF2 T-cell acute lymphoblastic leukemia
13 48337 11 1 2800000 Gain MIR675 T-cell acute lymphoblastic leukemia
14 48490 11 1 52900000 Duplication T-cell acute lymphoblastic leukemia
15 53563 11 31000000 36400000 Copy number WT1 T-cell acute lymphoblastic leukemia
16 57103 11 63100000 67100000 Gain MAP4K2 T-cell acute lymphoblastic leukemia
17 57104 11 63100000 67100000 Gain RASGRP2 T-cell acute lymphoblastic leukemia
18 60336 11 85300000 87900000 Loss PICALM T-cell acute lymphoblastic leukemia
19 60878 11 92800000 110400000 Copy number ATM T-cell acute lymphoblastic leukemia
20 61471 12 1 14800000 Deletion T-cell acute lymphoblastic leukemia
21 61531 12 1 35400000 Duplication T-cell acute lymphoblastic leukemia
22 61611 12 10000000 12600000 Loss CDKN1B T-cell acute lymphoblastic leukemia
23 61613 12 10000000 12600000 Loss MIR614 T-cell acute lymphoblastic leukemia
24 61779 12 10100000 14800000 Copy number CDKN1B T-cell acute lymphoblastic leukemia
25 74382 13 105800000 109100000 Gain TNFSF13B T-cell acute lymphoblastic leukemia
26 78375 13 50900000 55300000 Deletion DLEU7 T-cell acute lymphoblastic leukemia
27 78376 13 50900000 55300000 Deletion KCNRG T-cell acute lymphoblastic leukemia
28 82826 14 15600000 23600000 Deletion T-cell acute lymphoblastic leukemia
29 88309 6 135544145 135582003 Copy number MYB T-cell acute lymphoblastic leukemia
30 104069 16 66700000 70800000 Deletion CTCF T-cell acute lymphoblastic leukemia
31 108732 17 22200000 28800000 Duplication T-cell acute lymphoblastic leukemia
32 109390 17 25800000 31800000 Copy number NF1 T-cell acute lymphoblastic leukemia
33 109749 17 28800000 35400000 Deletion T-cell acute lymphoblastic leukemia
34 111430 17 3600000 6800000 Loss NLRP1 T-cell acute lymphoblastic leukemia
35 115247 17 55600000 58400000 Gain MSI2 T-cell acute lymphoblastic leukemia
36 115248 17 55600000 58400000 Gain VEZF1 T-cell acute lymphoblastic leukemia
37 115617 17 58400000 59900000 Gain MAP3K3 T-cell acute lymphoblastic leukemia
38 115618 17 58400000 59900000 Gain SMURF2 T-cell acute lymphoblastic leukemia
39 115619 17 58400000 59900000 Gain MIR633 T-cell acute lymphoblastic leukemia
40 115878 17 59900000 64600000 Gain PRKCA T-cell acute lymphoblastic leukemia
41 116600 17 68400000 72200000 Gain GPR142 T-cell acute lymphoblastic leukemia
42 116601 17 68400000 72200000 Gain GPRC5C T-cell acute lymphoblastic leukemia
43 121278 18 41800000 46400000 Loss SMAD4 T-cell acute lymphoblastic leukemia
44 124174 19 1 6900000 Gain MKNK2 T-cell acute lymphoblastic leukemia
45 131214 19 53800000 57600000 Gain FUT2 T-cell acute lymphoblastic leukemia
46 131215 19 53800000 57600000 Gain RASIP1 T-cell acute lymphoblastic leukemia
47 133723 19 6900000 12600000 Gain INSR T-cell acute lymphoblastic leukemia
48 133733 19 6900000 13900000 Deletion T-cell acute lymphoblastic leukemia
49 140125 2 19200000 27900000 Copy number NCOA1 T-cell acute lymphoblastic leukemia
50 140126 2 19200000 27900000 Copy number TP53I3 T-cell acute lymphoblastic leukemia

Expression for T-Cell Acute Lymphoblastic Leukemia

Search GEO for disease gene expression data for T-Cell Acute Lymphoblastic Leukemia.

Pathways for T-Cell Acute Lymphoblastic Leukemia

Pathways related to T-Cell Acute Lymphoblastic Leukemia according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.25 TAL1 LCK IL2 BCL10
2 11.96 LCK IL2 BAX ATM
3 11.64 BAX ATM ABL1
4 11.56 LCK BCL10 ATM
5 11.45 TSPAN7 TLX3 TLX1 LYL1 LMO2 BAX
6 11.25 IL2 ATM ABL1
7 11.01 NOTCH1 LYL1 LMO2
8
Show member pathways
10.47 BAX ATM ABL1

GO Terms for T-Cell Acute Lymphoblastic Leukemia

Biological processes related to T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.86 TLX1 TAL1 NOTCH1 LMO2 LMO1 IL2
2 regulation of apoptotic process GO:0042981 9.83 BCL10 BAX ATM ABL1
3 positive regulation of apoptotic process GO:0043065 9.83 NOTCH1 BCL10 BAX ATM ABL1
4 regulation of cell proliferation GO:0042127 9.81 TAL1 NOTCH1 LCK ABL1
5 negative regulation of neuron differentiation GO:0045665 9.63 TLX3 OLIG2 NOTCH1
6 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.58 BAX ATM ABL1
7 definitive hemopoiesis GO:0060216 9.55 TAL1 LYL1
8 thalamus development GO:0021794 9.54 TAL2 OLIG2
9 DNA damage induced protein phosphorylation GO:0006975 9.49 ATM ABL1
10 B cell apoptotic process GO:0001783 9.48 BCL10 BAX
11 regulation of hematopoietic stem cell differentiation GO:1902036 9.46 TAL1 LMO2 LMO1 ABL1
12 apoptotic process involved in embryonic digit morphogenesis GO:1902263 9.37 NOTCH1 BAX
13 neuron differentiation GO:0030182 9.35 TLX3 TAL1 OLIG2 NOTCH1 ABL1
14 regulation of T cell homeostatic proliferation GO:0046013 9.32 LMO1 IL2
15 post-embryonic development GO:0009791 8.92 TAL2 BAX ATM ABL1

Molecular functions related to T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein dimerization activity GO:0046983 9.46 TAL2 TAL1 OLIG2 LYL1
2 transcription coactivator activity GO:0003713 9.02 NUP98 NOTCH1 LMO2 BCL10 ABL1
3 kinase activator activity GO:0019209 8.96 IL2 BCL10

Sources for T-Cell Acute Lymphoblastic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....